Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.

NCT00174343 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00174343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00174343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2001
Completion date
September 30, 2006
Enrollment
46
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms